Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Anavex Life Sciences Announces Publication of Foundational Data

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
georgejjl Member Profile
 
Followed By 114
Posts 16,889
Boards Moderated 0
Alias Born 04/08/04
160x600 placeholder
BTIG Remains a Buy on Anavex Life Sciences (AVXL) TipRanks - 1/19/2022 1:45:28 AM
Anavex Life Sciences (AVXL) Gets a Buy Rating from H.C. Wainwright TipRanks - 1/11/2022 6:45:12 AM
JonesTrading Reaffirms Their Buy Rating on Anavex Life Sciences (AVXL) TipRanks - 1/10/2022 12:55:34 PM
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71 GlobeNewswire Inc. - 1/10/2022 7:00:00 AM
Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer GlobeNewswire Inc. - 1/6/2022 7:00:00 AM
Anavex Life Sciences Updates 2 Key Risk Factors TipRanks - 1/6/2022 6:01:37 AM
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference GlobeNewswire Inc. - 1/5/2022 7:00:00 AM
Dawson James Maintains a Buy Rating on Anavex Life Sciences (AVXL) TipRanks - 1/5/2022 4:10:29 AM
Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 12/14/2021 7:00:00 AM
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/29/2021 7:00:00 AM
Anavex Life provides key updates on clinical trials in rare genetic neurological disorders Seeking Alpha - 11/24/2021 9:40:36 AM
Anavex Life Sciences EPS misses by $0.39 Seeking Alpha - 11/24/2021 7:07:01 AM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results GlobeNewswire Inc. - 11/24/2021 7:00:00 AM
Notable earnings after Wednesday's close Seeking Alpha - 11/23/2021 5:35:23 PM
Anavex Life Sciences FY 2021 Earnings Preview Seeking Alpha - 11/23/2021 1:20:23 PM
Notable earnings before Wednesday's open Seeking Alpha - 11/23/2021 10:42:34 AM
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021 GlobeNewswire Inc. - 11/17/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease GlobeNewswire Inc. - 11/10/2021 7:00:00 AM
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference GlobeNewswire Inc. - 10/15/2021 7:00:00 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease GlobeNewswire Inc. - 10/13/2021 7:00:00 AM
Cassava down after phase 3 simufilam announcement; other Alzheimer's names follow Seeking Alpha - 10/6/2021 12:51:22 PM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/28/2021 8:00:00 AM
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021 GlobeNewswire Inc. - 9/27/2021 9:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:11:01 AM
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® GlobeNewswire Inc. - 9/27/2021 7:00:00 AM
georgejjl   Wednesday, 08/25/21 02:04:17 PM
Re: None
Post # of 346163 
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FXS (Autism)
Wed. 25 Aug 2021, 1:00pm

Results Highlight Reversal of Hyperactivity and Restoration of Associative Learning and Reduction of Anxiety, Phenotypes Associated with Fragile X Syndrome.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, announced that preclinical data of ANAVEX®2-73 (blarcamesine) in Fragile X syndrome were published in the peer-reviewed journal, Scientific Reports.

Fragile X syndrome is the most common form of inherited intellectual disability and the most frequent single gene cause of autism spectrum disorder with an estimated population of approximately 62,500 in the US and 1,088,500 worldwide. At present, there is no approved treatment for Fragile X syndrome.

The study evaluated doses of ANAVEX®2-73 in a validated animal model for the disease, which resulted in the reversal of hyperactivity and restoration of associative learning as well as reduction in anxiety-like and perseverative behaviors. In addition to showing a good safety profile, ANAVEX®2-73 also restored pAkt and BDNF levels in the hippocampus, which are signaling pathways particularly affected in Fragile X syndrome.

“Testing novel drugs that can safely improve the symptoms of Fragile X syndrome is a high priority,” said Walter E. Kaufmann, M.D., Chief Medical Officer of Anavex and corresponding author of the paper. “The present findings support the viability of SIGMAR1 as a therapeutic target in Fragile X syndrome, and the clinical potential of ANAVEX®2-73 (blarcamesine) in Fragile X syndrome and other neurodevelopmental disorders.”

The study, “Effects of the Sigma-1 Receptor Agonist Blarcamesine in a Murine Model of Fragile X Syndrome: Neurobehavioral Phenotypes and Receptor Occupancy,” is the basis for a Phase 2/3 ANAVEX®2-73 study in Fragile X syndrome. The fact that the investigation involved chronic administration, as opposed to acute dosing, provides additional evidence in favor of the clinical use of ANAVEX®2-73. Since the behavioral paradigms reflect the involvement of multiple cortical and subcortical regions, their marked improvement by ANAVEX®2-73 suggest widespread activation of SIGMAR1 by the drug and modulation of multiple neural pathways. Indeed, the observation of normalization of pAkt and BDNF levels after ANAVEX®2-73 administration, in a brain region critical for cognition and behavior, is also a finding with important implications for Fragile X syndrome and other similar disorders.

The study was supported by the FRAXA Research Foundation.

The full paper can be accessed online at:

https://www.nature.com/articles/s41598-021-94079-7

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (NASDAQ:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including pain, various types of cancer, Alzheimer’s disease (AD), Parkinson’s disease (PD), Rett syndrome (RS), and other central nervous system (CNS) diseases.

Media Contact
Company Name: Anavex Life Sciences
Contact Person: Andrew J. Barwicki
Email: Send Email
Phone: 516-662-9461
Country: United States
Website: https://www.anavex.com/

Good luck and GOD bless,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences